Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1949 1
1950 1
1951 2
1952 1
1953 1
1960 1
1963 1
1966 1
1969 2
1970 1
1971 1
1972 1
1973 2
1974 1
1975 2
1976 3
1977 2
1978 1
1979 3
1980 1
1982 4
1983 4
1985 3
1987 2
1988 1
1989 1
1990 1
1991 1
1992 2
1994 2
1995 2
1996 1
1997 1
1998 3
1999 1
2000 2
2001 4
2002 2
2003 5
2004 3
2005 4
2006 6
2007 3
2008 7
2009 3
2010 5
2011 4
2012 5
2013 6
2014 3
2015 4
2016 6
2017 5
2018 6
2019 8
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

143 results
Results by year
Filters applied: . Clear all
Page 1
New Uses of AbobotulinumtoxinA in Aesthetics.
Schlessinger J, Gilbert E, Cohen JL, Kaufman J. Schlessinger J, et al. Aesthet Surg J. 2017 May 1;37(suppl_1):S45-S58. doi: 10.1093/asj/sjx005. Aesthet Surg J. 2017. PMID: 28388720 Free PMC article. Review.
Beyond amelioration of facial lines, encouraging results have been seen with the use of BoNT-A to improve the appearance of hypertrophic and keloid scars and even to prevent them. ...Injections of BoNT-A have been shown to reduce signs and symptoms of acne, rosacea, and …
Beyond amelioration of facial lines, encouraging results have been seen with the use of BoNT-A to improve the appearance of hypertrop …
Psoriasis of the face and flexures.
van de Kerkhof PC, Murphy GM, Austad J, Ljungberg A, Cambazard F, Duvold LB. van de Kerkhof PC, et al. J Dermatolog Treat. 2007;18(6):351-60. doi: 10.1080/09546630701341949. J Dermatolog Treat. 2007. PMID: 17907013 Review.
Facial psoriasis occurs in 17-46% of psoriatics and flexural psoriasis is experienced by 6.8-36% of patients with psoriasis. ...Facial and flexural psoriasis cannot be regarded as distinct disease entities but rather as site variations. T
Facial psoriasis occurs in 17-46% of psoriatics and flexural psoriasis is experienced by 6.8-36% of patients with ps
Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials.
Paul C, Guenther L, Torii H, Sofen H, Burge R, Lin CY, Potts Bleakman A, Mallbris L, Poulin Y. Paul C, et al. J Eur Acad Dermatol Venereol. 2018 Jan;32(1):68-72. doi: 10.1111/jdv.14581. Epub 2017 Oct 6. J Eur Acad Dermatol Venereol. 2018. PMID: 28881462 Clinical Trial.

RESULTS: The combined database included 1133 patients with facial psoriasis and 1437 without. Patients treated with IXE whose facial psoriasis cleared had improved Dermatology Life Quality Index 0.1 responses (P < 0.01) compared with patients with

RESULTS: The combined database included 1133 patients with facial psoriasis and 1437 without. Patients treated with IXE whose …
Facial psoriasis: comparison of patients with and without facial involvement.
Young Park J, Hyun Rim J, Beom Choe Y, Il Youn J. Young Park J, et al. J Am Acad Dermatol. 2004 Apr;50(4):582-4. doi: 10.1016/s0190-9622(03)02793-2. J Am Acad Dermatol. 2004. PMID: 15034507
A few reports have suggested that facial involvement might be a sign of severe psoriasis. However, there have been no comparison studies on the severity of psoriasis between patients with and without facial involvement. OBJECTIVE: We sought to evaluate …
A few reports have suggested that facial involvement might be a sign of severe psoriasis. However, there have been no comparis …
Clinical features and severity of psoriasis: a comparison of facial and nonfacial involvement in Iran.
Keshavarz E, Roknsharifi S, Shirali Mohammadpour R, Roknsharifi M. Keshavarz E, et al. Arch Iran Med. 2013 Jan;16(1):25-8. Arch Iran Med. 2013. PMID: 23273232 Free article.
BACKGROUND: Facial involvement in psoriasis is accomplished with poor prognosis. In this study, clinical features and severity of psoriasis were compared between facial and nonfacial psoriasis involvement groups in Iran. ...Comparing different s …
BACKGROUND: Facial involvement in psoriasis is accomplished with poor prognosis. In this study, clinical features and severity …
Successful treatment of genital and facial psoriasis with tacrolimus ointment 0.1%.
Rallis E, Nasiopoulou A, Kouskoukis C, Roussaki-Schulze A, Koumantaki E, Karpouzis A, Arvanitis A. Rallis E, et al. Drugs Exp Clin Res. 2005;31(4):141-5. Drugs Exp Clin Res. 2005. PMID: 16223203 Clinical Trial.
Included in the study were 10 patients with a long-standing history of genital and facial psoriasis, partially controlled with periodic use of topical corticosteroids. ...In conclusion, tacrolimus ointment 0.1% seems to represent a safe new option for the treatment …
Included in the study were 10 patients with a long-standing history of genital and facial psoriasis, partially controlled with …
Relation between the Peripherofacial Psoriasis and Scalp Psoriasis.
Kim KH, Ahn JY, Park MY, Youn JI. Kim KH, et al. Ann Dermatol. 2016 Aug;28(4):422-6. doi: 10.5021/ad.2016.28.4.422. Epub 2016 Jul 26. Ann Dermatol. 2016. PMID: 27489422 Free PMC article.
OBJECTIVE: To analyze the epidemiologic characteristics, clinical features and subjective feelings of patients with facial psoriasis and to find out relationship between scalp psoriasis and facial involvement according to the facial types. METHO …
OBJECTIVE: To analyze the epidemiologic characteristics, clinical features and subjective feelings of patients with facial psorias
Psoriasis in special localizations.
Dopytalska K, Sobolewski P, Błaszczak A, Szymańska E, Walecka I. Dopytalska K, et al. Reumatologia. 2018;56(6):392-398. doi: 10.5114/reum.2018.80718. Epub 2018 Dec 23. Reumatologia. 2018. PMID: 30647487 Free PMC article. Review.
Psoriasis is a chronic inflammatory dermatosis affecting 1-3% of the general population. Patients with psoriasis represent a heterogeneous population with individual disease expression - different degrees and severity of skin involvement. ...Furthermore, genital
Psoriasis is a chronic inflammatory dermatosis affecting 1-3% of the general population. Patients with psoriasis represent a h
Facial involvement in Indian psoriatic patients and its association with disease severity and metabolic syndrome: A cross-sectional study.
Ranugha PSS, Bishnoi P, Chandrashekar L. Ranugha PSS, et al. Indian J Dermatol Venereol Leprol. 2019 Jul 17. doi: 10.4103/ijdvl.IJDVL_655_18. Online ahead of print. Indian J Dermatol Venereol Leprol. 2019. PMID: 31317874 Free article.
Facial psoriatics were divided into peripherofacial, centrofacial and mixed facial types. Disease severity was assessed using whole body, scalp, facial psoriasis area severity index scores and nail area psoriasis severity index scores. ...No sig
Facial psoriatics were divided into peripherofacial, centrofacial and mixed facial types. Disease severity was assessed using
Classification of facial psoriasis based on the distributions of facial lesions.
Woo SM, Choi JW, Yoon HS, Jo SJ, Youn JI. Woo SM, et al. J Am Acad Dermatol. 2008 Jun;58(6):959-63. doi: 10.1016/j.jaad.2008.02.006. Epub 2008 Mar 21. J Am Acad Dermatol. 2008. PMID: 18359126
Some authors have reported that a significant proportion of patients with psoriasis have facial involvement, and several reports have suggested that facial involvement is a marker of severe psoriasis. However, patients with facial psoriasis
Some authors have reported that a significant proportion of patients with psoriasis have facial involvement, and several repor …
143 results
Jump to page
Feedback